Regulation of insulin‑like growth factor signaling by metformin in endometrial cancer cells

Xie,Ya; Wang,Jing‑Lu; Ji,Mei; Yuan,Zhong‑Fu; Peng,Zheng; Zhang,Yi; Wen,Jian‑Guo; Shi,Hui‑Rong

doi:10.3892/ol.2014.2466

Regulation of insulin‑like growth factor signaling by metformin in endometrial cancer cells

Authors:
- Ya Xie
- Jing‑Lu Wang
- Mei Ji
- Zhong‑Fu Yuan
- Zheng Peng
- Yi Zhang
- Jian‑Guo Wen
- Hui‑Rong Shi
View Affiliations

Affiliations: Department of Gynecology and Obstetrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China, Institute of Clinical Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China
Published online on: August 20, 2014 https://doi.org/10.3892/ol.2014.2466
Pages: 1993-1999

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Obesity, diabetes and insulin resistance are marked risk factors that promote the development of type I endometrial cancer. Previous studies have demonstrated that insulin‑like growth factor 1 (IGF‑1) and IGF‑2 promote cell proliferation in endometrial cancer cells, while metformin reverses this effect and inhibits cell proliferation. However, the effects of metformin on the regulation of the IGF signaling pathway are unclear. The aim of this study was to investigate the regulation of IGF signaling by metformin in endometrial cancer cells, and to determine the effects of metformin combined with IGF‑1 receptor (IGF‑1R) inhibitor on cell proliferation and apoptosis. Cell proliferation was assessed following exposure of Ishikawa and HEC‑1B endometrial cancer cell lines to metformin and/or the IGF‑1R inhibitor, PPP. Apoptosis was assessed by TdT‑mediated dUTP nick end labeling assay. Metformin was observed to downregulate IGF‑1R and upregulate IGF binding protein‑1 (IGFBP‑1) mRNA and protein expression, while compound C, an adenosine monophosphate protein kinase inhibitor, reversed this effect. Metformin administered with PPP inhibited endometrial cancer cell proliferation to a greater degree than treatment with either agent alone. At high concentrations (1 or 2 mM), metformin induced apoptosis in endometrial cancer cells. Metformin combined with IGF‑1R axis inhibitors may act synergistically to kill tumor cells, as metformin was shown to delay and prevent IGF‑1R feedback. In conclusion, this study supported the results of animal studies and subclinical studies, demonstrating the feasibility of metformin combined with IGF‑1R axis inhibitors in the treatment of endometrial cancer.

View Figures

View References

1	Kitchener H: Management of endometrial cancer. Eur J Surg Oncol. 32:838–843. 2006.
2	Chia VM, Newcomb PA, Trentham-Dietz A and Hampton JM: Obesity, diabetes, and other factors in relation to survival after endometrial cancer diagnosis. Int J Gynecol Cancer. 17:441–446. 2007.
3	Calle EE, Rodriguez C, Walker-Thurmond K and Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 348:1625–1638. 2003.
4	Steiner E, Plata K, Interthal C, et al: Diabetes mellitus is a multivariate independent prognostic factor in endometrial carcinoma: a clinicopathologic study on 313 patients. Eur J Gynaecol Oncol. 28:95–97. 2007.
5	Augustin LS, Dal Maso L, Franceschi S, et al: Association between components of the insulin-like growth factor system and endometrial cancer risk. Oncology. 67:54–59. 2004.
6	Schernhammer ES, Holly JM, Hunter DJ, Pollak MN and Hankinson SE: Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocr Relat Cancer. 13:583–592. 2006.
7	Roy RN, Gerulath AH, Cecutti A and Bhavnani BR: Discordant expression of insulin-like growth factors and their receptor messenger ribonucleic acids in endometrial carcinomas relative to normal endometrium. Mol Cell Endocrinol. 153:19–27. 1999.
8	LeRoith D, Werner H, Beitner-Johnson D and Roberts CT Jr: Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev. 16:143–163. 1995.
9	Baserga R, Hongo A, Rubini M, Prisco M and Valentinis B: The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta. 1332:F105–F126. 1997.
10	Werner H: The molecular basis of IGF-I receptor gene expression in human cancer. Insulin-Like Growth Factors. LeRoith D, Zumkeller W and Baxter RC: Landes Bioscience; Austin, TX: pp. 346–356. 2003
11	Navarro M and Baserga R: Limited redundancy of survival signals from the type 1 insulin-like growth factor receptor. Endocrinology. 142:1073–1081. 2001.
12	Rutanen EM: Insulin-like growth factors in endometrial function. Gynecol Endocrinol. 12:399–406. 1998.
13	Oh JC, Wu W, Tortolero-Luna G, et al: Increased plasma levels of insulin-like growth factor 2 and insulin-like growth factor binding protein 3 are associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev. 13:748–752. 2004.
14	Pavelić J, Radaković B and Pavelić K: Insulin-like growth factor 2 and its receptors (IGF 1R and IGF 2R/mannose 6-phosphate) in endometrial adenocarcinoma. Gynecol Oncol. 105:727–735. 2007.
15	McCampbell AS, Broaddus RR, Loose DS and Davies PJ: Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium. Clin Cancer Res. 12:6373–6378. 2006.
16	Pengchong H and Tao H: Expression of IGF-1R, VEGF-C and D2-40 and their correlation with lymph node metastasis in endometrial adenocarcinoma. Eur J Gynaecol Oncol. 32:660–664. 2011.
17	Werner H and Bruchim I: The insulin-like growth factor-I receptor as an oncogene. Arch Physiol Biochem. 115:58–71. 2009.
18	Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA and Bae-Jump VL: Metformin is a potent inhibitor of endometrial cancer cell proliferation - implications for a novel treatment strategy. Gynecol Oncol. 116:92–98. 2010.
19	Rocha GZ, Dias MM, Ropelle ER, et al: Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth. Clin Cancer Res. 17:3993–4005. 2011.
20	Xie Y, Wang YL, Yu L, et al: Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. J Steroid Biochem Mol Biol. 126:113–120. 2011.
21	Parazzini F, La Vecchia C, Negri E, et al: Diabetes and endometrial cancer: an Italian case-control study. Int J Cancer. 81:539–542. 1999.
22	Grady D and Ernster VL: Endometrial cancer. Cancer Epidemiology and Prevention. Schottenfeld D and Fraumeni JF: 2nd edition. Oxford University Press; Oxford; pp. 1058–1089. 1996
23	Ouban A, Muraca P, Yeatman T and Coppola D: Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol. 34:803–808. 2003.
24	Petridou E, Koukoulomatis P, Alexe DM, Voulgaris Z, Spanos E and Trichopoulos D: Endometrial cancer and the IGF system: a case-control study in Greece. Oncology. 64:341–345. 2003.
25	Chen TW, Liang YN, Feng D, et al: Metformin inhibits proliferation and promotes apoptosis of HER2 positive breast cancer cells by downregulating HSP90. J BUON. 18:51–56. 2013.
26	Quentin T, Steinmetz M, Poppe A and Thoms S: Metformin differentially activates ER stress signaling pathways without inducing apoptosis. Dis Model Mech. 5:259–269. 2012.
27	Olmos D, Martins AS, Jones RL, Alam S, Scurr M and Judson IR: Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing’s Sarcoma: Reality and Expectations. Sarcoma. 2011:4025082011.
28	Gualberto A, Hixon ML, Karp DD, et al: Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. Br J Cancer. 104:68–74. 2011.
29	de Bono JS, Attard G, Adjei A, et al: Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res. 13:3611–3616. 2007.
30	Dowling RJ, Zakikhani M, Fantus IG, Pollak M and Sonenberg N: Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 67:10804–10812. 2007.
31	Shell SA, Lyass L, Trusk PB, Pry KJ, Wappel RL and Bacus SS: Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells. Cell Cycle. 7:1769–1775. 2008.
32	Vazquez-Martin A, Oliveras-Ferraros C, del Barco S, Martin-Castillo B and Menendez JA: The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy. Ann Oncol. 20:592–595. 2009.
33	Vazquez-Martin A, Oliveras-Ferraros C and Menendez JA: The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle. 8:88–96. 2009.
34	Alimova IN, Liu B, Fan Z, et al: Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle. 8:909–915. 2009.
35	Liu B, Fan Z, Edgerton SM, et al: Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle. 8:2031–2040. 2009.
36	Hadad SM, Fleming S and Thompson AM: Targeting AMPK: a new therapeutic opportunity in breast cancer. Crit Rev Oncol Hematol. 67:1–7. 2008.
37	Cazzaniga M, Bonanni B, Guerrieri-Gonzaga A and Decensi A: Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiol Biomarkers Prev. 18:701–705. 2009.
38	Pollak M: Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 8:915–928. 2008.
39	Carracedo A, Baselga J and Pandolfi PP: Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors. Cell Cycle. 7:3805–3809. 2008.
40	Vazquez-Martin A, Oliveras-Ferraros C, Del Barco S, Martin-Castillo B and Menendez JA: If mammalian target of metformin indirectly is mammalian target of rapamycin, then the insulin-like growth factor-1 receptor axis will audit the efficacy of metformin in cancer clinical trials. J Clin Oncol. 27:e207–e209. 2009.